Wednesday, March 21, 2018
Company News: Page (1) of 1 - 09/28/17 Email this story to a friend. email article Print this page (Article printing at page facebook
FDA Grants Priority Review for Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer

(September 28, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines